Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT

被引：31
作者：
Akcali, C.
Zincirkeser, S.
Erbagcy, Z.
Akcali, A.
Halac, M.
Durak, G.
Sager, S.
Sahin, E.
机构：
[1] Gaziantep Univ, Sch Med, Dept Dermatol, Gaziantep, Turkey
[2] Gaziantep Univ, Sch Med, Nucl Med & PET Ctr, Gaziantep, Turkey
[3] Gaziantep Univ, Sch Med, Dept Neurol, Gaziantep, Turkey
[4] Istanbul Univ, Cerrahpasa Med Sch, Nucl Med & PET Ctr, Istanbul, Turkey
来源：
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | 2007年 / 35卷 / 04期
关键词：
melanoma; metastases; fluorodeoxyglucose (FDG); positron emission tomography (PET); computed tomography (CT);
D O I：
10.1177/147323000703500415
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
This study aimed to detect metastases in patients with stage III or IV cutaneous melanoma by F-18-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT). Thirty-nine patients with clinically evident stage III or IV melanoma underwent whole-body FDG-PET/CT scans for metastatic disease and these results were compared with those of biopsy. Scans for 38 of the patients were evaluated; one patient's scan could not be evaluated. There were 11 true-positive, two false-positive, 24 true-negative and one false-negative scans for the detection of melanoma metastases, with sensitivity 91%, specificity 92%, accuracy 92%, and positive and negative predictive values 84% and 96%, respectively. False-positive FDG-PET/CT scans were due to sarcoidosis in the lung and infected cyst in the liver. It is concluded that FDG-PET/CT scanning has high sensitivity and specificity for detecting stage III or IV metastatic melanoma.
引用
收藏
页码：547 / 553
页数：7
相关论文
共 39 条
[1]   Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose [J].
Avril, N ;
Dose, J ;
Janicke, F ;
Bense, S ;
Ziegler, S ;
Laubenbacher, C ;
Romer, W ;
Pache, H ;
Herz, M ;
Allgayer, B ;
Nathrath, W ;
Graeff, H ;
Schwaiger, M .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) :1848-1857
[2]  
Beyer T, 2000, J NUCL MED, V41, P1369
[3]  
Brand CU, 1997, CANCER, V79, P2345
[4]   Whole body PET/CT for initial staging of choroidal melanoma [J].
Finger, PT ;
Kurli, M ;
Reddy, S ;
Tena, LB ;
Pavlick, AC .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2005, 89 (10) :1270-1274
[5]  
Freedberg I., 2003, FITZPATRICKS DERMATO, P917, DOI [10.1016/j.jaad.2003.12.039, DOI 10.1016/J.JAAD.2003.12.039]
[6]   Whole-body fluorine-18 fluordeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in staging of advanced uveal melanoma [J].
Freudenberg, LS ;
Schueler, AO ;
Beyer, T ;
Antoch, G ;
Kühl, H ;
Bornfeld, N ;
Bockisch, A ;
Egelhof, T .
SURVEY OF OPHTHALMOLOGY, 2004, 49 (05) :537-540
[7]   The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: Impact on surgical decision making [J].
Gulec, SA ;
Faries, MB ;
Lee, CC ;
Kirgan, D ;
Glass, C ;
Morton, DL ;
Essner, R .
CLINICAL NUCLEAR MEDICINE, 2003, 28 (12) :961-965
[8]   Update on the incidence and mortality from melanoma in the United States [J].
Hall, HI ;
Miller, DR ;
Rogers, JD ;
Bewerse, B .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 40 (01) :35-42
[9]   Effectiveness of positron emission tomography for the detection of melanoma metastases [J].
Holder, WD ;
White, RL ;
Zuger, JH ;
Easton, EJ ;
Greene, FL .
ANNALS OF SURGERY, 1998, 227 (05) :764-771
[10]   The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma [J].
Jadvar, H ;
Johnson, DL ;
Segall, GM .
CLINICAL NUCLEAR MEDICINE, 2000, 25 (01) :48-51
1234